CN114839358A - Sample analyzer and sample analyzing method - Google Patents

Abstract

The application relates to the field of biological detection, and particularly discloses a sample analyzer and a sample analysis method, wherein the sample analyzer comprises: a blood routine detection channel; a specific protein detection channel; an analysis unit; the controller is configured to respond to a novel coronavirus infection detection instruction, control the blood routine detection channel to detect the sample to be detected so as to obtain blood routine parameters, control the specific protein detection channel to detect the sample to be detected so as to obtain specific protein parameters, control the analysis unit to obtain analysis parameters related to novel coronavirus infection from the blood routine parameters and the specific protein parameters of the sample to be detected, and control the analysis unit to judge whether the analysis parameters meet preset conditions. By the method, the early rapid detection of the novel coronavirus can be met.

Description

Sample analyzer and sample analyzing method

Technical Field

The present application relates to the field of biological detection, and in particular, to a sample analyzer and a sample analysis method.

Background

In 2020, infectious diseases caused by the new coronavirus 2019-nCoV, also known as new coronavirus pneumonia (Corona Virus Disease 2019, COVID-19), were developed worldwide. The novel coronavirus has the characteristics of strong infectivity, high propagation speed, long incubation period and the like, and is particularly important for accurately, conveniently and quickly detecting patients and suspected patients who are contacted with the coronavirus. At present, the detection mode aiming at the novel coronavirus is mainly direct detection of the virus, namely nucleic acid detection, which is to detect certain specific nucleic acid sequences in virus genes; the detection has high sensitivity but low speed, and the method has high requirements on fields and detection personnel and is not suitable for large-scale screening.

Disclosure of Invention

The present application is directed to solving at least one of the problems in the prior art. Therefore, an object of the present application is to provide a sample analyzer and a sample analysis method, which can quickly and conveniently measure the blood general parameters and specific protein parameters by using the sample analyzer, and prompt to quickly obtain the "analysis parameters related to the novel coronavirus infection" according to the blood general parameters and specific protein parameters, so as to make an early and quick prejudgment on "whether the sample to be detected is related to the novel coronavirus infection", so that medical staff can quickly respond to the early and prevent the novel coronavirus from further spreading.

A first aspect of the present application provides a sample analyzer comprising: a blood routine detection channel; a specific protein detection channel; an analysis unit; the controller is configured to respond to a novel coronavirus infection detection instruction, control the blood routine detection channel to detect a sample to be detected so as to obtain blood routine parameters, control the specific protein detection channel to detect the sample to be detected so as to obtain specific protein parameters, control the analysis unit to obtain analysis parameters related to novel coronavirus infection from the blood routine parameters and the specific protein parameters of the sample to be detected, and control the analysis unit to judge whether the analysis parameters meet preset conditions.

In a second aspect, the present application provides a sample analysis method, based on the foregoing sample analyzer, the method including: responding to a novel coronavirus infection detection instruction, detecting a sample to be detected through a blood conventional detection channel to obtain blood conventional parameters, and detecting the sample to be detected through a specific protein detection channel to obtain specific protein parameters; obtaining analysis parameters related to the novel coronavirus infection from blood conventional parameters and specific protein parameters of a sample to be detected by an analysis unit; and judging whether the analysis parameters meet preset conditions or not through the analysis unit.

Be different from prior art, adopt the sample analysis appearance of this application can detect blood conventional parameter and specific protein parameter simultaneously with same branch's sample, convenient operation, and can measure blood conventional parameter and specific protein parameter fast, conveniently, and then through obtaining the analysis parameter relevant with novel coronavirus infection from blood conventional parameter and specific protein parameter, with acquire "the analysis parameter relevant with novel coronavirus infection fast", and then whether "treat that the sample is relevant with novel coronavirus infection" makes early quick prejudgement, so that medical staff makes quick response, prevent the further diffusion of novel coronavirus.

Additional aspects and advantages of the present application will be set forth in part in the description which follows and, in part, will be obvious from the description, or may be learned by practice of the present application.

Drawings

The above and/or additional aspects and advantages of the present application will become apparent and readily appreciated from the following description of the embodiments, taken in conjunction with the accompanying drawings of which:

fig. 1 is a schematic structural view of a sample analyzer according to a first embodiment of the present application;

FIG. 2 is a schematic diagram of the structure of a specific protein detection channel of the sample analyzer of FIG. 1;

fig. 3 is a schematic structural view of a sample analyzer according to a second embodiment of the present application;

fig. 4 is a schematic structural view of a sample analyzer according to a third embodiment of the present application;

fig. 5 is a schematic structural view of a sample analyzer according to a fourth embodiment of the present application;

FIG. 6 is a schematic flow chart of a sample analysis method according to a fifth embodiment of the present application;

fig. 7 is a schematic flow chart of a sample analysis method according to a sixth embodiment of the present application.

Detailed Description

The technical solutions in the embodiments of the present application will be described clearly and completely with reference to the drawings in the embodiments of the present application, and it is obvious that the described embodiments are only a part of the embodiments of the present application, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present application.

Throughout the specification, unless otherwise specifically noted, terms used herein should be understood as having meanings as commonly used in the art. Accordingly, unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. If there is a conflict, the present specification will control.

It should be noted that in the embodiments of the present application, the terms "comprises", "comprising" or any other variation thereof are intended to cover a non-exclusive inclusion, so that a method or apparatus including a series of elements includes not only the explicitly recited elements but also other elements not explicitly listed or inherent to the method or apparatus. Without further limitation, an element defined by the phrase "comprising an … …" does not exclude the presence of other related elements in a method or apparatus including the element (e.g., steps in a method or elements in an apparatus, such as a part of a circuit, a part of a processor, a part of a program or software, etc.).

It should be noted that the terms "first \ second \ third" referred to in the embodiments of the present application merely distinguish similar objects, and do not represent a specific ordering for the objects, and it should be understood that "first \ second \ third" may exchange a specific order or sequence when allowed. It should be understood that "first \ second \ third" distinct objects may be interchanged under appropriate circumstances such that the embodiments of the present application described herein may be implemented in an order other than those illustrated or described herein.

The inventor of the application finds that the blood routine parameters and the specific protein parameters of the novel coronavirus infection positive blood sample can be subjected to specific change compared with the negative sample, and the specific change can indicate that the sample to be detected is a sample related to the novel coronavirus infection, and even can indicate the infection degree or development trend of the novel coronavirus. Based on this, the present embodiment provides a sample analyzer 100 and a sample analyzing method.

The solution provided by the embodiment of the application has the advantages of high speed and low cost, that is, the specific protein detection and the routine blood detection can be completed within 15 minutes from the acquisition to the test, and the specific protein detection and the routine blood detection are completed by the sample analyzer 100, so that the detection cost is low.

As shown in fig. 1, the present application proposes a sample analyzer 100 comprising: a specific protein detection channel 10, a blood routine detection channel 20, an analysis unit 30, and a controller 40.

The controller 40 is configured to, in response to the new coronavirus infection detection instruction, control the blood routine detection channel 20 to detect the sample to be detected to obtain blood routine parameters, control the specific protein detection channel 10 to detect the sample to be detected to obtain specific protein parameters, control the analysis unit 30 to obtain analysis parameters related to the new coronavirus infection from the blood routine parameters and the specific protein parameters of the sample to be detected, and control the analysis unit 30 to determine whether the analysis parameters satisfy a preset condition to determine whether the sample to be detected is related to the new coronavirus infection.

Be different from prior art, the sample analysis appearance 100 that adopts this application can detect blood conventional parameter and specific protein parameter simultaneously with a sample, convenient operation to can measure blood conventional parameter and specific protein parameter fast, conveniently, and then through obtaining the analysis parameter relevant with novel coronavirus infection from blood conventional parameter and specific protein parameter, with the analysis parameter relevant with novel coronavirus infection of acquireing fast, "whether relevant with novel coronavirus infection to" treat the sample and make early quick prejudgement "so that medical staff makes quick response, prevent the further diffusion of novel coronavirus.

In some embodiments, analyzing the parameters includes: at least one blood-normal parameter and/or a combination of at least two blood-normal parameters, and at least one protein-specific parameter and/or a combination of at least two protein-specific parameters.

In some embodiments, analyzing the parameters includes: leukocyte count, lymphocyte percentage, neutrophil percentage, erythrocyte distribution width standard deviation, erythrocyte distribution width variation coefficient, erythrocyte number, macrocyte ratio, microcyte ratio, platelet distribution width standard deviation, mean platelet volume, macrocyte ratio, high fluorescence intensity cell percentage, mean erythrocyte hemoglobin concentration, neutrophil gelatinase-associated lipocalin (NGAL), neutrophil/lymphocyte ratio (NLR), lymphocyte/monocyte ratio (LMR), platelet/lymphocyte ratio (PLR), and at least one of C-reactive protein (CRP) concentration, serum amyloid a protein (SAA) concentration, serum amyloid a protein/C-reactive protein ratio (SAA/CRP).

Specifically, particles such as White Blood Cells (WBCs), Red Blood Cells (RBCs), Platelets (PLTs), Nucleated Red Blood Cells (NRBCs), and Reticulocytes (RETs) in blood are counted and classified, i.e., blood routine examination. White Blood Cells (WBCs) can be classified as monocytes, lymphocytes, eosinophils, basophils, and neutrophils. Among them, Neutrophil gelatinase-associated lipocalin (NGAL), also called lipocalin-2, is a trace protein expressed by neutrophils and some epithelial cells such as renal tubules. NGAL was initially isolated from human neutrophils and measurement of NGAL in the blood is an excellent method of distinguishing between acute infections caused by bacteria and viruses. And (NLR) has important predictive value for the diagnosis of the novel coronavirus pneumonia and the clinical course progress of the severe patients, and according to statistical analysis, the probability of generating COVID-19 is increased by 1.752 times for every increase of one unit of NLR, so that the method has important predictive value for early identification of COVID-19.

C-reactive protein (CRP) and serum amyloid a protein (SAA) are early inflammatory markers of infectious diseases and are important for the diagnosis of bacterial infections, viral infections, tissue infections and for the assessment of the degree of inflammation. C-reactive protein (CRP) is an acute phase-reactive protein synthesized by liver, and as the acute phase-reactive protein, the protein rises several hours after the bacteria infect organisms, the peak value can be reached within 48 hours, and when the CRP concentration is more than 10mg/L, the bacteria are possibly infected.

Serum amyloid a protein (SAA) is a precursor substance of tissue amyloid a and belongs to an acute phase reaction protein. Serum amyloid a protein (SAA) is a normal component present at low levels in blood. When the human body has virus or bacteria infectious inflammation, active lesion and large-area tissue injury, the disease is quickly raised. Particularly in acute infections (48-72 hours) and rapidly decreases in the recovery phase of the disease. Therefore, serum amyloid A protein (SAA) is an extremely effective auxiliary diagnostic index when infecting body viruses, and the half-life of the serum amyloid A protein (SAA) is short and only 50min, so that the serum amyloid A protein (SAA) can well reflect the severity of diseases in time.

The inventor finds that NGAL has important predictive value for judging whether a sample to be detected is related to the novel coronavirus infection in the process of researching blood conventional parameters of a large number of novel coronavirus infection samples. Thus, in some embodiments, the analysis parameters comprise at least NGAL or a combination of NGAL with other blood-normal parameters, such as a combination of NGAL with white blood cell count, a combination of NGAL with neutrophil percentage, a combination of NGAL with neutrophil/lymphocyte ratio (NLR), a combination of NGAL with lymphocyte/monocyte ratio (LMR), a combination of NGAL with platelet/lymphocyte ratio (PLR). Therefore, the judgment of 'whether the sample to be detected is related to the novel coronavirus infection' can be carried out by utilizing the blood conventional parameters.

The inventor finds that the ratio of the neutrophils to the lymphocytes has important predictive value for judging whether a sample to be detected is related to the novel coronavirus infection in the process of researching the blood conventional parameters of a large number of novel coronavirus infection samples. Thus, in some embodiments, the analysis parameters comprise at least NLR or NLR in combination with other blood-normal parameters, such as NLR in combination with white blood cell count, NLR in combination with neutrophil percentage, NLR in combination with lymphocyte/monocyte ratio (LMR), NLR in combination with platelet/lymphocyte ratio (PLR). Therefore, the judgment of 'whether the sample to be detected is related to the novel coronavirus infection' can be carried out by utilizing the blood conventional parameters.

The inventor finds that SAA/CRP has important predictive value for judging whether a sample to be detected is related to the novel coronavirus infection in the process of researching specific protein parameters of a large number of novel coronavirus infection samples. Thus, in some embodiments, the analytical parameters comprise at least SAA/CRP or a combination of SAA/CRP and other specific protein parameters, such as a combination of SAA/CRP and serum amyloid a protein (SAA) concentration, a combination of SAA/CRP and C-reactive protein (CRP) concentration. Therefore, the judgment of whether the sample to be detected is related to the novel coronavirus infection or not can be carried out by utilizing the specific protein parameters.

In some embodiments, the sample to be tested can be judged to be a sample associated with a novel coronavirus infection when the amount of NLR is above a predetermined level and the amount of SSA/CRP is above a predetermined level. For example, NLR is more than or equal to 4.00, and SSA/CRP is more than or equal to 10.00, the sample to be detected can be judged to be the sample related to the novel coronavirus infection.

In some embodiments, analyzing the parameters includes: neutrophil/lymphocyte ratio (NLR), serum amyloid a protein (SAA) concentration, and serum amyloid a protein/C-reactive protein ratio (SSA/CRP).

Furthermore, in the long-term research and development process, the inventor of the application finds that under normal conditions, the content of SAA in a body is extremely low, but after the exogenous virus stimulation, a large amount of SAA can be synthesized and secreted by liver cells, and the SAA level in blood can be increased by 1000 times within 5-6 h, so that the SAA is obviously increased in the early stage of the novel coronavirus infection; CRP is not increased or slightly increased when the novel coronavirus is infected, so that SAA/CRP is obviously increased at the early stage of the novel coronavirus infection; when the body is infected with the novel coronavirus, the level of the NLR change is far less than the SAA change, and therefore, in some embodiments, when the amount of the SAA is higher than a predetermined level, the amount of the NLR is lower than a predetermined level, and the SAA/CRP is higher than a predetermined level, the sample to be tested can be judged as a sample associated with the novel coronavirus infection. For example, when SAA is greater than or equal to 100.00mg/L, NLR is less than or equal to 3.50 and SSA/CRP is greater than or equal to 8.00, the sample to be detected can be judged to be a sample related to the novel coronavirus infection.

By the mode, based on the characteristic that SAA is obviously increased in the early stage of the novel coronavirus infection, CRP is not increased or slightly increased in the novel coronavirus infection generally, NLR is increased and has positive correlation with the occurrence probability of COVID-19 but lacks sensitivity, so that the simultaneous detection of the three components can provide powerful data for judging the novel coronavirus infection. Therefore, the blank of the current rapid detection of the novel coronavirus infection can be just made up by jointly detecting the conventional parameters and the specific protein parameters of the blood, particularly the neutrophil/lymphocyte ratio (NLR), the serum amyloid A protein (SAA) concentration and the serum amyloid A protein/C reactive protein ratio (SSA/CRP), so that the basis is brought for the diagnosis of the novel coronavirus.

In some embodiments, as shown in fig. 2, the specific protein detection channel 10 comprises: detection cell 11, transmitter 12, receiver 13, detection circuitry 14.

The transmitter 12 and the receiver 13 are respectively disposed at both sides of the detection cell 11 such that an optical path between the transmitter 12 and the receiver 13 passes through the liquid in the detection cell 11, and the receiver 13 is configured to convert a received optical signal into an electrical signal.

The detection circuit 14 is connected to the receiver 13, and the detection circuit 14 is configured to process the electrical signal to detect at least one specific protein in the detection cell 11.

In some embodiments, as shown in fig. 3, the sample analyzer 100 further comprises: a sampling unit 20, a plurality of cell bodies 30 and a reagent unit 40. Wherein, a plurality of cell bodies 30 at least include: a first specific protein reaction tank 31, a second specific protein reaction tank 32, and a blood routine detection tank 33. The sampling unit 20 is configured to aspirate a sample, wherein the sample may be a blood sample comprising serum or plasma. Reagent unit 40 is configured to distribute treatment reagent to a number of cell bodies 30. Several cell bodies 30 are configured to accommodate a sample to be detected, wherein the sample to be detected is a liquid after the sample reacts with a treatment reagent.

The blood routine detecting cell 33 may be a white blood cell reaction cell and/or a red blood cell counting cell. The leukocyte reaction cell is a place for the blood sample to react with the hemolytic agent. The erythrocyte counting cell is used for counting erythrocytes and thrombocytes in a blood sample. The first specific protein reaction tank 31 may be a CRP reaction tank, which is a place for the blood sample, the hemolytic agent, and the antibody reagent to react together; the second specific protein reaction cell 32 may be a SAA reaction cell for a site where a blood sample, a hemolytic agent, and an antibody reagent are reacted together.

In some embodiments, as shown in fig. 4, the sample analyzer 100 further comprises: a mode setting unit 50.

The mode setting unit 50 is configured to set a blood routine detection mode, a specific protein detection mode, or a novel coronavirus infection detection mode. The controller 40 is further configured to control the actions of the sampling unit 20, the reagent unit 40 and the analysis unit 30 in response to the novel coronavirus infection detection mode so as to acquire only analysis parameters related to the novel coronavirus infection.

Specifically, when the blood routine detecting mode is set by the mode setting unit 50, the controller 40 is further configured to control the actions of the sampling unit 20, the reagent unit 40, and the analyzing unit 30 so as to acquire only the blood routine parameter in response to the blood routine detecting mode.

When the specific protein detection mode is set by the mode setting unit 50, the controller 40 is further configured to control the actions of the sampling unit 20, the reagent unit 40, and the analysis unit 30 in response to the specific protein detection mode so as to acquire only the specific protein parameter.

When the blood routine detection-specific protein detection mode is set by the mode setting unit 50, the controller 40 is further configured to control the actions of the sampling unit 20, the reagent unit 40, and the analysis unit 30 in response to the blood routine detection-specific protein detection mode so as to acquire only the blood routine parameter and the specific protein parameter.

When the mode setting unit 50 sets the novel coronavirus infection detection mode, the controller 40 is further configured to control actions of the sampling unit 20, the reagent unit 40, and the analysis unit 30 in response to the novel coronavirus infection detection mode so as to acquire only analysis parameters related to the novel coronavirus infection.

In some embodiments, as shown in fig. 5, the sample analyzer 100 further comprises: a display unit 60. The display unit 60 is configured to display information related to blood general parameters, specific protein parameters, and alarm information related to a novel coronavirus infection. For example, the display unit 60 is configured as a user interface.

The controller 40 is further configured to control the display unit 60 to display alarm information related to a novel coronavirus infection when the analysis parameter satisfies a preset condition. Wherein, the alarm information related to the novel coronavirus infection at least comprises: the method is used for prompting alarm information related to the novel coronavirus infection of the sample to be detected and/or alarm information for prompting the development trend of the novel coronavirus infection of the sample to be detected.

An embodiment of the present application further provides a sample analysis method, as shown in fig. 6, based on the sample analyzer 100 in the foregoing embodiment, where the method includes:

s10: in response to the new coronavirus infection detection instruction, the sample to be detected is detected through the blood routine detection channel 20 to obtain blood routine parameters, and the sample to be detected is detected through the specific protein detection channel 10 to obtain specific protein parameters.

S20: analysis parameters related to the novel coronavirus infection are obtained from the blood routine parameters and the specific protein parameters of the sample to be tested by the analysis unit 30.

S30: it is determined by the analyzing unit 30 whether the analysis parameter satisfies a preset condition.

Wherein the analysis parameters include: at least one blood-normal parameter and/or a combination of at least two blood-normal parameters, and at least one protein-specific parameter and/or a combination of at least two protein-specific parameters.

Optionally, the analysis parameters include: leukocyte count, lymphocyte percentage, neutrophil percentage, erythrocyte distribution width standard deviation, erythrocyte distribution width variation coefficient, erythrocyte number, macrocyte ratio, microcyte ratio, platelet distribution width standard deviation, mean platelet volume, macrocyte ratio, high fluorescence intensity cell percentage, mean erythrocyte hemoglobin concentration, neutrophil gelatinase-associated lipocalin (NGAL), neutrophil/lymphocyte ratio (NLR), lymphocyte/monocyte ratio (LMR), platelet/lymphocyte ratio (PLR), and at least one of C-reactive protein (CRP) concentration, serum amyloid a protein (SAA) concentration, serum amyloid a protein/C-reactive protein ratio (SAA/CRP).

In some embodiments, the sample to be tested can be judged to be a sample associated with a novel coronavirus infection when the amount of NLR is above a predetermined level and the amount of SSA/CRP is above a predetermined level. For example, NLR is more than or equal to 4.00, and SSA/CRP is more than or equal to 10.00, the sample to be detected can be judged to be the sample related to the novel coronavirus infection.

In some embodiments, analyzing the parameters includes: neutrophil/lymphocyte ratio (NLR), serum amyloid a protein (SAA) concentration, and serum amyloid a protein/C-reactive protein ratio (SSA/CRP).

Furthermore, in the long-term research and development process, the inventor of the application finds that under normal conditions, the content of SAA in a body is extremely low, but after the exogenous virus stimulation, a large amount of SAA can be synthesized and secreted by liver cells, and the SAA level in blood can be increased by 1000 times within 5-6 h, so that the SAA is obviously increased in the early stage of the novel coronavirus infection; CRP is not increased or slightly increased when the novel coronavirus is infected, so that SAA/CRP is obviously increased at the early stage of the novel coronavirus infection; when the body is infected with the novel coronavirus, the level of the NLR change is far less than the SAA change, and therefore, in some embodiments, when the amount of the SAA is higher than a predetermined level, the amount of the NLR is lower than a predetermined level, and the SAA/CRP is higher than a predetermined level, the sample to be tested can be judged as a sample associated with the novel coronavirus infection. For example, when SAA is greater than or equal to 100.00mg/L, NLR is less than or equal to 3.50 and SSA/CRP is greater than or equal to 8.00, the sample to be detected can be judged to be a sample related to the novel coronavirus infection.

By the mode, based on the characteristic that SAA is obviously increased in the early stage of the novel coronavirus infection, CRP is not increased or slightly increased in the novel coronavirus infection generally, NLR is increased and has positive correlation with the occurrence probability of COVID-19 but lacks sensitivity, so that the simultaneous detection of the three components can provide powerful data for judging the novel coronavirus infection. Therefore, the blank of the current rapid detection of the novel coronavirus infection can be just made up by jointly detecting the conventional parameters and the specific protein parameters of the blood, particularly the neutrophil/lymphocyte ratio (NLR), the serum amyloid A protein (SAA) concentration and the serum amyloid A protein/C reactive protein ratio (SSA/CRP), so that the basis is brought for the diagnosis of the novel coronavirus.

Further, as shown in fig. 7, after step S30, the sample analysis method further includes:

s40: when the analysis parameters satisfy the preset conditions, the control display unit 60 displays alarm information related to the novel coronavirus infection. Wherein, the alarm information related to the novel coronavirus infection at least comprises: the method is used for prompting alarm information related to the novel coronavirus infection of the sample to be detected and/or the alarm information for prompting the development trend of the novel coronavirus infection of the sample to be detected.

An embodiment of the present application further provides a computer-readable storage medium, in which a computer program is stored, and the computer program, when executed by a processor, implements the sample analysis method.

Wherein the storage medium comprises: a U-disk, a removable hard disk, a Read-Only Memory (ROM), a Random Access Memory (RAM), a magnetic disk or an optical disk, and other various media capable of storing program codes.

In this way, the sample analyzer 100 of the present application can simultaneously detect the conventional parameters and specific protein parameters of blood by using the same sample, and is convenient to operate, and can quickly and conveniently detect the conventional parameters and specific protein parameters of blood, and further acquire the analysis parameters related to the novel coronavirus infection from the conventional parameters and specific protein parameters of blood, so as to quickly acquire the analysis parameters related to the novel coronavirus infection, and further make early quick prejudgment on whether the sample to be detected is related to the novel coronavirus infection, so that medical staff can make quick response and prevent the further diffusion of the novel coronavirus.

In the several embodiments provided in the present application, it should be understood that the disclosed method and apparatus may be implemented in other manners. For example, the above-described device embodiments are merely illustrative, and for example, the division of the modules or units is only one logical division, and other divisions may be realized in practice, for example, a plurality of units or components may be combined or integrated into another system, or some features may be omitted, or not executed.

The units described as separate parts may or may not be physically separate, and parts displayed as units may or may not be physical units, may be located in one place, or may be distributed on a plurality of network units. Some or all of the units can be selected according to actual needs to achieve the purpose of the embodiment.

In addition, functional units in the embodiments of the present application may be integrated into one processing unit, or each unit may exist alone physically, or two or more units may be integrated into one unit. The integrated unit can be realized in a form of hardware, and can also be realized in a form of a software functional unit.

The above description is only an example of the present application and is not intended to limit the scope of the present application, and all modifications of equivalent structures and equivalent processes, which are made by the contents of the specification and the drawings, or which are directly or indirectly applied to other related technical fields, are intended to be included within the scope of the present application.

Claims (10)

1. A sample analyzer, comprising:

a blood routine detection channel;

a specific protein detection channel;

an analysis unit;

the controller is configured to respond to a novel coronavirus infection detection instruction, control the blood routine detection channel to detect a sample to be detected so as to obtain blood routine parameters, control the specific protein detection channel to detect the sample to be detected so as to obtain specific protein parameters, control the analysis unit to obtain analysis parameters related to novel coronavirus infection from the blood routine parameters and the specific protein parameters of the sample to be detected, and control the analysis unit to judge whether the analysis parameters meet preset conditions.

2. The sample analyzer of claim 1,

the analysis parameters include: at least one blood-normal parameter and/or a combination of at least two blood-normal parameters, and at least one protein-specific parameter and/or a combination of at least two protein-specific parameters.

3. The sample analyzer of claim 2,

the analysis parameters include: leukocyte count, lymphocyte percentage, neutrophil percentage, erythrocyte distribution width standard deviation, erythrocyte distribution width variation coefficient, erythrocyte number, macrocyte ratio, microcyte ratio, platelet distribution width standard deviation, mean platelet volume, macrocyte ratio, high fluorescence intensity cell percentage, mean erythrocyte hemoglobin concentration, neutrophil gelatinase-associated lipocalin (NGAL), neutrophil/lymphocyte ratio (NLR), lymphocyte/monocyte ratio (LMR), platelet/lymphocyte ratio (PLR), and at least one of C-reactive protein (CRP) concentration, serum amyloid a protein (SAA) concentration, serum amyloid a protein/C-reactive protein ratio (SAA/CRP).

4. The sample analyzer of claim 3,

the analysis parameters include: neutrophil/lymphocyte ratio (NLR), serum amyloid a protein (SAA) concentration, and serum amyloid a protein/C-reactive protein ratio (SSA/CRP).

5. The sample analyzer of claim 1,

the specific protein detection channel comprises:

a detection cell;

a transmitter;

a receiver, wherein the transmitter and the receiver are respectively arranged at two sides of the detection cell, so that an optical path between the transmitter and the receiver passes through the liquid in the detection cell, and the receiver is configured to convert a received optical signal into an electrical signal;

a detection circuit coupled to the receiver, the detection circuit configured to process the electrical signal to detect at least one specific protein in the detection cell.

6. The sample analyzer of claim 1, further comprising:

a sampling unit configured to aspirate a sample;

a number of cell bodies configured to accommodate the sample to be detected, the number of cell bodies including at least: a first specific protein reaction pool, a second specific protein reaction pool and a blood conventional detection pool;

a reagent unit configured to dispense a treatment reagent to the number of cells;

wherein the sample to be detected is liquid obtained after the sample reacts with the processing reagent.

7. The sample analyzer of claim 6, further comprising:

a mode setting unit configured to set a blood routine detection mode, a specific protein detection mode, or a novel coronavirus infection detection mode;

the controller is further configured to control actions of the sampling unit, the reagent unit, and the analysis unit in response to a novel coronavirus infection detection mode so as to acquire only analysis parameters related to a novel coronavirus infection.

8. The sample analyzer of claim 1, further comprising:

a display unit configured to display information related to blood general parameters, specific protein parameters, and alarm information related to a novel coronavirus infection;

the controller is further configured to control the display unit to display alarm information related to a novel coronavirus infection when the analysis parameter satisfies a preset condition;

wherein the warning information related to the novel coronavirus infection at least comprises: the alarm information is used for prompting the alarm information related to the novel coronavirus infection of the sample to be detected and/or the alarm information used for prompting the development trend of the novel coronavirus infection of the sample to be detected.

9. A sample analysis method based on the sample analyzer of any one of claims 1 to 8, the method comprising:

responding to a novel coronavirus infection detection instruction, detecting a sample to be detected through a blood conventional detection channel to obtain blood conventional parameters, and detecting the sample to be detected through a specific protein detection channel to obtain specific protein parameters;

obtaining analysis parameters related to the novel coronavirus infection from the blood conventional parameters and the specific protein parameters of the sample to be detected through an analysis unit;

and judging whether the analysis parameters meet preset conditions or not through the analysis unit.

10. The method of claim 9,

the analysis parameters include: at least one blood-normal parameter and/or a combination of at least two blood-normal parameters, and at least one protein-specific parameter and/or a combination of at least two protein-specific parameters.

Images